PATENT CLAIM ANALYSIS

Application Number: 15982038
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "249000"]

Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.

Claim (Index 14):
A method of treating a thromboembolic disorder according to  claim 12 , wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, atrial fibrillation, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 93.0
- Lexical Diversity: 1.17949
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15643891', '15183051', '14799681', '14350411', '14350417']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8088215649094734
- 35 USC 102 Novelty (BERT): 0.5339063305661729
- Combined Prediction Score: 0.7813300414751434
- Mean Citation Score: 315.033496
- Max Citation Score: 316.3271200000001
- Similarity Product: 135.6759081301785

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test